Prospective clinical surveillance for severe acute respiratory illness and COVID-19 vaccine effectiveness in Kenyan hospitals during the COVID-19 pandemic.

Publication date: Nov 05, 2024

There are limited data from sub-Saharan Africa describing the demographic characteristics, clinical features and outcome of patients admitted to public hospitals with severe acute respiratory infections during the COVID-19 pandemic. We conducted a prospective longitudinal hospital-based sentinel surveillance between May 2020 and December 2022 at 16 public hospitals in Kenya. All patients aged above 18 years admitted to adult medical wards in the participating hospitals were included. We collected data on demographic and clinical characteristics, SARS-CoV-2 infection and COVID-19 vaccination status and, admission episode outcomes. We determined COVID-19 vaccine effectiveness (VE) against admission with SARS-CoV-2 positive severe acute respiratory illness (SARI) (i. e., COVID-19) and progression to inpatient mortality among patients admitted with SARI, using a test-negative case control design. Of the 52,636 patients included in the study, 17,950 (34. 1%) were admitted with SARI. The median age was 50 years. Patients were equally distributed across sexes. Pneumonia was the most common diagnosis at discharge. Hypertension, Human Immunodeficiency Virus (HIV) infection and Diabetes Mellitus were the most common chronic comorbidities. SARS-CoV-2 test results were positive in 2,364 (27. 9%) of the 8,471 patients that underwent testing. After adjusting for age, sex and presence of a chronic comorbidity, SARI patients were more likely to progress to inpatient mortality compared to non-SARI patients regardless of their SARS-CoV-2 infection status (adjusted odds ratio (aOR) for SARI and SARS-CoV-2 negative patients 1. 22, 95% CI 1. 10-1. 37; and aOR for SARI and SARS-CoV-2 positive patients 1. 32, 95% CI 1. 24-1. 40). After adjusting for age, sex and presence of a chronic comorbidity, COVID-19 VE against progression to inpatient mortality following admission with SARI for those with a confirmed vaccination status was 0. 59 (95% CI 0. 27-0. 77). We have provided a comprehensive description of the demographic and clinical pattern of admissions with SARI in Kenyan hospitals during the COVID-19 pandemic period as well as the COVID-19 VE for these patients. These data were useful in providing situational awareness during the first three years of the pandemic in Kenya and informing national response measures.

Open Access PDF

Concepts Keywords
December Adolescent
Demographic Adult
Inpatient Aged
Kenya COVID-19
Pneumonia COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Female
Hospital surveillance
Hospitalization
Hospitals, Public
Humans
Kenya
Longitudinal Studies
Male
Middle Aged
Pandemics
Prospective Studies
SARS-CoV-2
Sentinel Surveillance
Vaccine effectiveness
Vaccine Efficacy
Young Adult

Semantics

Type Source Name
disease MESH COVID-19 pandemic
disease MESH respiratory infections
pathway REACTOME SARS-CoV-2 Infection
disease MESH Pneumonia
disease MESH Hypertension
disease IDO immunodeficiency
disease MESH infection
disease MESH Diabetes Mellitus
disease MESH comorbidity
disease MESH Infectious Diseases
pathway REACTOME Reproduction
drug DRUGBANK Methylergometrine
disease MESH HIV infection
pathway REACTOME HIV Infection
disease IDO pathogen
drug DRUGBANK Fenamole
disease IDO country
drug DRUGBANK Tretamine
drug DRUGBANK Ethionamide
disease MESH syndrome
drug DRUGBANK Dexamethasone
drug DRUGBANK Ranitidine
drug DRUGBANK Oxygen
drug DRUGBANK Ilex paraguariensis leaf
drug DRUGBANK Aspartame
disease MESH pulmonary tuberculosis
disease IDO blood
disease MESH hypothermia
disease MESH Hyperthermia
disease MESH Leukopenia
disease MESH Leukocytosis
disease MESH Anemia
disease MESH Malaria
pathway KEGG Malaria
disease MESH death
disease MESH co infection
drug DRUGBANK Coenzyme M
disease MESH community spread
disease IDO facility
drug DRUGBANK Etoperidone
drug DRUGBANK Inosine
disease MESH Miras
disease IDO contact tracing
disease MESH cardiovascular risk
drug DRUGBANK Dihydroxy(oxo)molybdenum(6+)
drug DRUGBANK Tacrine
disease MESH inflammation
drug DRUGBANK Trestolone
disease MESH influenza
disease MESH emergency
disease MESH Severe Acute Respiratory Syndrome

Original Article

(Visited 3 times, 1 visits today)